We are excited to welcome a new colleague to the Tubulis Team. Olivier Marcq joins us as Vice President CMC. He is an expert in bioconjugation therapeutics with more than 15 years of leadership expertise in the pharmaceutical industry, including big pharma companies, such as Pfizer and Astellas Pharma, as well as biotech start-ups. His profound experience encompasses CMC operation and strategy and GMP manufacturing as well as R&D and early phase development of biologics, particularly ADCs and conjugate vaccines. Olivier will use his long-standing know-how to advance and accelerate the development of our uniquely matched, next-generation ADC candidates towards clinical evaluation.
